Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Inclusion Criteria: * Recipient must have signed a voluntary, informed consent in accordance with institutional and federal guidelines * Recipients must have histopathologically confirmed diagnosis of multiple myeloma * Age: * Stratum I (TMI containing arm): 18-60 years of age * Stratum II (non TMI arm): 18-70 years of age * Patients with primary progressive disease on induction therapy with new targeted therapies * Relapsed/refractory disease on new targeted therapies, i.e. thalidomide, lenalidomide, bortezomib, or other new novel agents such as carfilzomib, pomalidomide * Patients with relapsed multiple myeloma following previous autologous stem cell transplant * Plasma cell leukemia at diagnosis * High-risk patients with presence of chromosome 17p deletion (\> 60%) in the bone marrow by fluorescence in situ hybridization (FISH); patients are not required to have prior autologous stem cell transplant * Able to lie supine for approximately 60 minutes, the anticipated duration of each treatment session * Performance status evaluated by Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Scales (KPS) patients must have a score of 0-II (ECOG) or \>= 70% (KPS) * Cardiac ejection fraction \>= 50% by multiple gate acquisition (MUGA) scan and/or by echocardiogram * Forced expiratory volume in one second (FEV1) \>= 50% * Diffusing lung capacity for carbon monoxide (DLCO) \>= 50% * Creatinine clearance or glomerular filtration rate (GFR) \>= 60 ml/min * Serum bil…